The companies plan to focus initially on development of two monoclonal antibody candidates, with the aim of initiating Phase II clinical development in the next three to five months.
The company was founded to develop base editing, a form of gene editing that alters genes at the single-letter level rather than using the "cutting" technique typical of CRISPR/Cas9. Beam had filed to go public in September, aiming at raising $100 million.
Choosing the right brain injury rehabilitation program is a critical decision that can shape the future for you or your loved one.
The latest round of funding, led by Chinese investors, brings the total amount of money raised by the company, co-founded by CRISPR pioneer Jennifer Doudna, to more than $70 million.
Jiankui He, who sparked controversy in 2018 with the announcement that he had used gene-editing technology on human embryos, has been sentenced to prison and fined, Chinese state media reported. His former professor at Rice University remains under investigation by the school.
The company, officially launched in 2018 after operating in stealth mode for a year, is developing technologies to enable genome editing at the single-letter level, as opposed to the "cutting" of DNA and RNA normally used in CRISPR/Cas9.
Researchers using CRISPR-Cas9 gene editing on cancer cell lines found that even when certain drugs' putative molecular targets were removed, they still killed the cancer cells, indicating their mechanisms were not understood.
Incorporating aquatic therapy can enhance patient outcomes and shorten recovery times for health care professionals. In the Chicago suburbs, the demand for such programs is rising.
One of the four sites of the trial, in a rare form of inherited blindness, is currently listed as open for enrollment, and the companies plan to dose the first patient soon.
The company, partnered with Beam Therapeutics, Verily Life Sciences and academic institutions, plans to use gene editing to tackle coronary artery disease. However, experience with gene therapy indicates cost could be a hurdle.
The 18 signatories emphasized that the moratorium wouldn't constitute a ban or include gene editing for research or treatment of diseases, but called on nations to develop a framework to govern the practice.
The company is developing means using CRISPR/Cas9 to edit genomes at the single-letter level, as opposed to the DNA- and RNA-cutting method usually employed.
Healthcare in the U.S. today exists in a complex, fragmented and costly system, and the people this system is designed for deserve a holistic approach to best address their individual health needs.
Shares of gene-editing companies were down Tuesday morning following the news, but analysts sought to reassure investors about Editas.
The company said it would use the funding to expand its single-cell DNA sequencing platform into CRISPR applications and global markets.
Tango Therapeutics - which uses CRISPR-based screening to find drug candidates - will receive $50 million upfront and be eligible for up to $1.7 billion in milestones, royalties and other payments.
The financing, led by Thiel's Founders Fund, will help the company expand its reach into Europe and Asia while building up its manufacturing capabilities.
The agency also accepted the two companies' IND to begin the Phase I/II study of CTX001 in patients with sickle cell disease, sending CRISPR shares up more than 11 percent Thursday morning.